Dr. Amber Salzman, PhD - CEO & Director, Epic Bio - Editing The Epigenome To Treat Complex Diseases

Dr. Amber Salzman, Ph.D. is Chief Executive Officer and Director of Epic Bio (https://epic-bio.com/), a fascinating therapeutic epigenome editing startup, developing therapies to modulate gene expression at the level of the epigenome, which just recently emerged from stealth mode with a $55 million funding round.

Dr. Salzman has more than 30 years of experience in the pharmaceuticals industry. Before joining Epic Bio, Dr. Salzman served as the president and CEO of Ohana Biosciences, pioneering the industry’s first sperm biology platform. Before Ohana, she served as the president and CEO of Adverum Biotechnologies and was a co-founder of Annapurna, SAS, where she served as President and CEO before its merger with Avalanche Biotechnologies to become Adverum. In that role, she saw the company’s stock price double.

Dr. Salzman began her career as a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for operations in drug development across multiple therapeutic areas, overseeing global clinical trials with over 30,000 enrolled patients, managing 1,600 employees and a $1.25B budget.

Following her time at GSK, Dr. Salzman served as the CEO of Cardiokine, a pharmaceutical company that developed treatments for the prevention of cardiovascular diseases and saw the successful sale of the company to Cornerstone Therapeutics.

Dr. Salzman currently serves on the Osler Diagnostics (UK) and AviadoBio (UK) Boards.

Dr. Salzman received her bachelor’s degree from Temple University in computer science and holds a Ph.D. in mathematics from Bryn Mawr College.

In addition to advocating for patients living with rare diseases, Dr. Salzman leads the Stop ALD Foundation, a non-profit medical research foundation focused on developing novel gene therapies for adrenoleukodystrophy (ALD).